Published in Thromb Haemost on October 31, 1988
Overwhelming tPA release, not PAI-1 degradation, is responsible for hyperfibrinolysis in severely injured trauma patients. J Trauma Acute Care Surg (2016) 0.93
Endogenous plasma activated protein C levels and the effect of enoxaparin and drotrecogin alfa (activated) on markers of coagulation activation and fibrinolysis in pulmonary embolism. Crit Care (2011) 0.89
Severe congenital protein C deficiency: the use of protein C concentrates (human) as replacement therapy for life-threatening blood-clotting complications. Biologics (2008) 0.82
Plasma fibrinogen level and the risk of major cardiovascular diseases and nonvascular mortality: an individual participant meta-analysis. JAMA (2005) 5.60
Venous thrombosis due to poor anticoagulant response to activated protein C: Leiden Thrombophilia Study. Lancet (1994) 5.58
Increased risk of venous thrombosis in oral-contraceptive users who are carriers of factor V Leiden mutation. Lancet (1994) 5.45
Hemostatic factors and the risk of myocardial infarction or sudden death in patients with angina pectoris. European Concerted Action on Thrombosis and Disabilities Angina Pectoris Study Group. N Engl J Med (1995) 5.24
Microparticle-associated tissue factor activity: a link between cancer and thrombosis? J Thromb Haemost (2006) 3.03
High levels of coagulation factor XI as a risk factor for venous thrombosis. N Engl J Med (2000) 2.39
Atomic force microscopy: a novel approach to the detection of nanosized blood microparticles. J Thromb Haemost (2009) 2.33
FcgammaRI (CD64) contributes substantially to severity of arthritis, hypersensitivity responses, and protection from bacterial infection. Immunity (2002) 2.31
Interaction of coagulation defects and cardiovascular risk factors: increased risk of myocardial infarction associated with factor V Leiden or prothrombin 20210A. Circulation (1998) 2.26
Increased levels of factor VIII and fibrinogen in patients with venous thrombosis are not caused by acute phase reactions. Thromb Haemost (1999) 2.04
Saturated but not mono-unsaturated fatty acids induce apoptotic cell death in neonatal rat ventricular myocytes. J Lipid Res (1997) 2.03
Congenital protein C deficiency and venous thromboembolism. A study of three Dutch families. N Engl J Med (1983) 2.03
Inherited thrombophilia: Part 1. Thromb Haemost (1996) 2.00
The putative factor IX gene promoter in hemophilia B Leyden. Blood (1988) 1.98
Increased risk of venous thrombosis in carriers of hereditary protein C deficiency defect. Lancet (1993) 1.96
von Willebrand factor and its propeptide: the influence of secretion and clearance on protein levels and the risk of venous thrombosis. J Thromb Haemost (2006) 1.84
Fibrinolytic factors and the risk of myocardial infarction or sudden death in patients with angina pectoris. ECAT Study Group. European Concerted Action on Thrombosis and Disabilities. Circulation (1996) 1.80
High levels of factor IX increase the risk of venous thrombosis. Blood (2000) 1.61
Nucleotide sequence of a cDNA for a member of the human 90-kDa heat-shock protein family. Gene (1987) 1.60
Cerebral haemorrhagic infarction in young patients with hereditary protein C deficiency: evidence for "spontaneous" cerebral venous thrombosis. Br Med J (Clin Res Ed) (1985) 1.58
Different effects of oral contraceptives containing different progestogens on protein S and tissue factor pathway inhibitor. J Thromb Haemost (2007) 1.55
Hereditary protein S deficiency: clinical manifestations. Ann Intern Med (1987) 1.53
Reduced response to activated protein C is associated with increased risk for cerebrovascular disease. Ann Intern Med (1996) 1.48
Preparation of lyophilized partial thromboplastin time reagent composed of synthetic phospholipids: usefulness for monitoring heparin therapy. Clin Chem (1997) 1.46
Thrombin activatable fibrinolysis inhibitor and the risk for deep vein thrombosis. Blood (2000) 1.45
Activated protein C resistance: a comparison between two clotting assays and their relationship to the presence of the factor V Leiden mutation. Br J Haematol (1996) 1.39
Protein C deficiency in a Dutch family with thrombotic disease. Thromb Haemost (1982) 1.37
Isolation and chemical characterization of phosphatidyl glycerol from spinach leaves. Biochim Biophys Acta (1965) 1.35
Inherited thrombophilia: Part 2. Thromb Haemost (1996) 1.34
Haplotypes of the EPCR gene, plasma sEPCR levels and the risk of deep venous thrombosis. J Thromb Haemost (2004) 1.33
Elevated factor VIII levels and the risk of thrombosis. Arterioscler Thromb Vasc Biol (2001) 1.33
Activated protein C decreases plasminogen activator-inhibitor activity in endothelial cell-conditioned medium. Blood (1985) 1.33
Procoagulant activity of endocardial vegetations and blood monocytes in rabbits with Streptococcus sanguis endocarditis. Thromb Haemost (1989) 1.31
Determination of plasma protein S--the protein cofactor of activated protein C. Thromb Haemost (1985) 1.31
Microparticle-associated tissue factor activity, venous thromboembolism and mortality in pancreatic, gastric, colorectal and brain cancer patients. J Thromb Haemost (2012) 1.29
Disruption of a binding site for hepatocyte nuclear factor 4 results in hemophilia B Leyden. Proc Natl Acad Sci U S A (1992) 1.29
Prevalence of protein C deficiency in the healthy population. Thromb Haemost (1995) 1.28
Systematically missing confounders in individual participant data meta-analysis of observational cohort studies. Stat Med (2009) 1.27
Activated protein C resistance as an additional risk factor for thrombosis in protein C-deficient families. Blood (1994) 1.27
Microparticle-associated tissue factor activity in cancer patients with and without thrombosis. J Thromb Haemost (2009) 1.19
The effect of some instruments for prothrombin time testing on the International Sensitivity Index (ISI) of two rabbit tissue thromboplastin reagents. Thromb Haemost (1989) 1.19
Contribution of factor VII genotype to activated FVII levels. Differences in genotype frequencies between northern and southern European populations. Arterioscler Thromb Vasc Biol (1997) 1.17
Stimulation of monocyte tissue factor expression in an in vitro model of bacterial endocarditis. Infect Immun (1994) 1.17
The use of a functional and immunologic assay for plasma protein C in the study of the heterogeneity of congenital protein C deficiency. Thromb Haemost (1984) 1.17
The contributions of Ca2+, phospholipids and tissue-factor apoprotein to the activation of human blood-coagulation factor X by activated factor VII. Biochem J (1990) 1.17
Prediction of deep vein thrombosis after elective hip replacement surgery by preoperative clinical and haemostatic variables: the ECAT DVT Study. European Concerted Action on Thrombosis. Thromb Haemost (1999) 1.17
Hemophilia B Leyden: a sex-linked hereditary disorder that improves after puberty. N Engl J Med (1982) 1.16
Protective effect of calcium in the plasmin degradation of fibrinogen and fibrin fragments D. Thromb Res (1977) 1.15
Cysteine-mutations in von Willebrand factor associated with increased clearance. J Thromb Haemost (2005) 1.14
An in vitro analysis of the combination of hemophilia A and factor V(LEIDEN). Blood (1997) 1.14
Two genes homologous with human protein S cDNA are located on chromosome 3. Thromb Haemost (1987) 1.14
Protein C and the development of skin necrosis during anticoagulant therapy. Thromb Haemost (1983) 1.13
Protein C deficiency in two Austrian families. Thromb Haemost (1983) 1.12
Factor VIII binds to von Willebrand factor via its Mr-80,000 light chain. Eur J Biochem (1987) 1.10
Two novel point mutations correlate with an altered developmental expression of blood coagulation factor IX (hemophilia B Leyden phenotype). Blood (1989) 1.09
Genotypic variation in the promoter region of the protein C gene is associated with plasma protein C levels and thrombotic risk. Arterioscler Thromb Vasc Biol (1995) 1.08
ABO blood group genotypes and the risk of venous thrombosis: effect of factor V Leiden. J Thromb Haemost (2005) 1.08
Considerations on the true value of the international normalized ratio in the control of oral anticoagulant therapy. Br J Haematol (1994) 1.07
Molecular characterization of a type I quantitative factor V deficiency in a thrombosis patient that is "pseudo homozygous" for activated protein C resistance. Thromb Haemost (1997) 1.07
The binding of aurovertin to mitochondria, and its effect on mitochondrial respiration. Biochim Biophys Acta (1973) 1.06
Hereditary protein S deficiency and venous thrombo-embolism. A study in three Dutch families. Thromb Haemost (1985) 1.06
Intron-exon organization of the active human protein S gene PS alpha and its pseudogene PS beta: duplication and silencing during primate evolution. Biochemistry (1990) 1.05
Characterization of the molecular defect in factor VR506Q. J Biol Chem (1995) 1.05
Congenital protein C deficiency and thrombotic disease in nine French families. Br Med J (Clin Res Ed) (1984) 1.04
Ischemic stroke in young patients with activated protein C resistance. A report of three cases belonging to three different kindreds. Stroke (1995) 1.04
A Dutch family with moderately severe hemophilia B (factor IXHeerde) has a missense mutation identical to that of factor IX London 2. Nucleic Acids Res (1989) 1.02
Inconsistency of association between type 1 von Willebrand disease phenotype and genotype in families identified in an epidemiological investigation. Thromb Haemost (1999) 1.02
The role of factor VIII in the activation of human blood coagulation factor X by activated factor IX. Thromb Haemost (1985) 1.01
Factor X levels, polymorphisms in the promoter region of factor X, and the risk of venous thrombosis. Thromb Haemost (2001) 1.01
G20210A is a functional mutation in the prothrombin gene; effect on protein levels and 3'-end formation. J Thromb Haemost (2004) 1.00
Monitoring heparin therapy by the activated partial thromboplastin time--the effect of pre-analytical conditions. Thromb Haemost (1987) 0.99
Fibrinogen Marburg: a homozygous case of dysfibrinogenemia, lacking amino acids A alpha 461-610 (Lys 461 AAA-->stop TAA). Blood (1992) 0.99
Influence of monocytes and antibiotic treatment on tissue factor activity of endocardial vegetations in rabbits infected with Streptococcus sanguis. Infect Immun (1996) 0.99
Combined hereditary deficiency of the sixth component of complement and factor VIII coagulant activity in a Dutch family. Clin Exp Immunol (1982) 0.99
Localization of factor VIII-procoagulant antigen: an immunohistological survey of the human body using monoclonal antibodies. Blood (1986) 0.97
Pathways in the activation of human coagulation factor X. Biochem J (1980) 0.97
Preeclampsia and genetic risk factors for thrombosis: a case-control study. Am J Obstet Gynecol (1999) 0.96
Five novel intragenic dimorphisms in the human interleukin-1 genes combine to high informativity. Cytokine (1996) 0.96
Binding of human blood-coagulation Factors IXa and X to phospholipid membranes. Biochem J (1984) 0.96
A Dutch pedigree with mild hemophilia B with a missense mutation in the first EGF domain (factor IXOud en Nieuw Gastel). Nucleic Acids Res (1989) 0.95
Apparent different thrombotic tendency in patients with factor V Leiden and protein C deficiency due to selection of patients. Blood (1996) 0.95
Molecular basis of fibrinogen Naples associated with defective thrombin binding and thrombophilia. Homozygous substitution of B beta 68 Ala----Thr. J Clin Invest (1992) 0.94
Plasma fibrinogen gamma' chain content in the thrombotic microangiopathy syndrome. J Thromb Haemost (2006) 0.93
Elevated plasma fibrinogen: cause or consequence of cardiovascular disease? Arterioscler Thromb Vasc Biol (1998) 0.93
The spectrum of genetic defects in a panel of 40 Dutch families with symptomatic protein C deficiency type I: heterogeneity and founder effects. Blood (1991) 0.93
Role of monocytes in experimental Staphylococcus aureus endocarditis. Infect Immun (2000) 0.93
Molecular basis for fibrinogen Dusart (A alpha 554 Arg-->Cys) and its association with abnormal fibrin polymerization and thrombophilia. J Clin Invest (1993) 0.93
Polymorphisms in the prothrombin gene and their association with plasma prothrombin levels. Thromb Haemost (2001) 0.92
Inhibition of thrombin-mediated factor V activation contributes to the anticoagulant activity of fibrinogen γ'. J Thromb Haemost (2013) 0.92
Two mutations of the factor IX gene including a donor splice consensus deletion and a point mutation in a Dutch patient with severe hemophilia B. Thromb Haemost (1990) 0.92
A reduced sensitivity for activated protein C in the absence of factor V Leiden increases the risk of venous thrombosis. Blood (1999) 0.92
Factor IX Deventer-evidence for the heterogeneity of hemophilia BM. Thromb Haemost (1982) 0.92
Functional characterization of transcription factor binding sites for HNF1-alpha, HNF3-beta (FOXA2), HNF4-alpha, Sp1 and Sp3 in the human prothrombin gene enhancer. J Thromb Haemost (2003) 0.92
Polymorphism 10034C>T is located in a region regulating polyadenylation of FGG transcripts and influences the fibrinogen gamma'/gammaA mRNA ratio. J Thromb Haemost (2007) 0.92
Protein S deficiency associated with "juvenile" arterial and venous thromboses. Thromb Haemost (1986) 0.91
The mechanism of inhibition by oligomycin of oxidative phosphorylation in mitochondria. Biochim Biophys Acta (1974) 0.90